Hepatocellular carcinoma
Conditions
Interventions
Control group:Transcatheter arterial chemoembolization (TACE)
Experimental group:TACE+Nivolumab Hepatic Artery Perfusion
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged >=18 and <=75 years; 2.Clinical or pathological diagnosis of HCC; 3.Complete clinical, laboratory and imaging data; 4.The liver tumor load is less than 70% (the tumor occupies the volume of the whole liver), there is no main portal vein tumor thrombus or there is main portal vein tumor thrombus, but the collateral is well established; 5.Liver cancer CNLC stage IIb-IIIb; 6.Child-Pugh grade A or B; 7.ECOG -PS score: 0-2; 8.There are no other contraindications for angiography (e.g., contrast agent allergy, uncontrolled infection, uncorrected coagulation disorders, etc.); 9.No contraindications for the use of PD-1 (e.g. autoimmune diseases, history of organ transplantation, etc.); 10.Subjects voluntarily join the study, sign an informed consent form, and be able to cooperate with follow-up and complete the research project.
Exclusion criteria
Exclusion criteria: 1.Patients with abnormal coagulation function (INR>1.5 or prothrombin time (PT)>ULN+4 seconds), with bleeding tendency or receiving thrombolysis or anticoagulation therapy; 2.Patients with grade II or above bone marrow suppression; 3.Patients with active infectious disease; 4.Patients with severe heart, lung, kidney, brain and other basic diseases, unable to tolerate intervention therapy; 5.Patients cannot tolerate a complete treatment cycle (>=2 times) and cannot objectively evaluate the therapeutic effect.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS);Disease control rate (DCR); | — |
Countries
China
Contacts
Public ContactWang Maoqiang
Chinese PLA General Hospital
Outcome results
None listed